Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.